Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1124/jpet.115.224212PMID 26116630
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.

  2015cited by this paper
• Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

  2014influential reference
• Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-Related Peptide Activity

  2014influential reference
• Anti-CGRP antibodies: a new approach to migraine prevention.

  2014influential reference
• Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain.

  2014influential reference
• Localization of CGRP Receptor Components, CGRP, and Receptor Binding Sites in Human and Rhesus Cerebellar Cortex

  2013cited by this paper
• The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats

  2013influential reference
• Emerging Target‐Based Paradigms to Prevent and Treat Migraine

  2013cited by this paper
• PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy

  2013cited by this paper
• A role for the sensory neuropeptide calcitonin gene‐related peptide in endothelial cell proliferation in vivo

  2012cited by this paper
• Calcitonin gene-related peptide promotes cellular changes in trigeminal neurons and glia implicated in peripheral and central sensitization

  2011cited by this paper
• Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

  2011influential reference
• CGRP and Adrenomedullin as Pain-Related Peptides

  2010cited by this paper
• Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

  2010cited by this paper
• Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).

  2010influential reference
• Calcitonin gene-related peptide, adrenomedullin and flushing.

  2009cited by this paper
• Calcitonin Gene-Related Peptide8-37 Antagonizes Capsaicin-Induced Vasodilation in the Skin: Evaluation of a Human in Vivo Pharmacodynamic Model

  2008cited by this paper
• Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

  2008cited by this paper
• Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of

  2008cited by this paper
• Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging.

  2007cited by this paper
• Expression of calcitonin gene-related peptide, adrenomedullin, and receptor modifying proteins in human adipose tissue and alteration in their expression with menopause status

  2007cited by this paper
• Calcitonin gene‐related peptide enhances TTX‐resistant sodium currents in cultured dorsal root ganglion neurons from adult rats

  2005cited by this paper
• Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay.

  2005cited by this paper
• Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

  2004cited by this paper
• Localization of functional calcitonin gene-related peptide binding sites in a subpopulation of cultured dorsal root ganglion neurons.

  2002cited by this paper
• The capsaicin receptor: a heat-activated ion channel in the pain pathway

  1997cited by this paper
• Calcitonin gene-related peptide is a potent vasodilator

  1985cited by this paper

• Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real-life multicenter study.

  2025cites this paper
• The Effect of Fremanezumab on Pain in Patients with Complex Regional Pain Syndrome: Study Protocol of a Randomized, Double-Blind, Proof-of-Concept, Placebo-Controlled Trial

  2025cites this paper
• IUPHAR Review: Navigating the role of preclinical models in pain research.

  2024cites this paper
• Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium

  2023cites this paper
• Baseline demographics and disease characteristics of patients with episodic or chronic cluster headache: data from two phase 3 randomized clinical trials in Europe and North America

  2023cites this paper
• Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine

  2023cites this paper
• Galcanezumab modulates Capsaicin-induced C-fiber reactivity

  2022cites this paper
• Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients

  2022cites this paper
• Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?

  2021cites this paper
• Human Models

  2021cites this paper
• Optimization of capsaicin‐induced dermal blood flow measurement by laser Doppler imaging in cynomolgus macaque

  2021cites this paper
• Current advances in the management of cluster headaches

  2021cites this paper
• The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions

  2021cites this paper
• Relationship of the Calcitonin Gene‐Related Peptide Monoclonal Antibody Galcanezumab Pharmacokinetics and Capsaicin‐Induced Dermal Blood Flow in Healthy Subjects

  2021cites this paper
• Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.

  2020cites this paper
• Galcanezumab for the prevention of migraine.

  2020cites this paper
• Drug profile: galcanezumab for prevention of cluster headache

  2020cites this paper
• Therapeutic Management: When and What

  2020cites this paper
• Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 Studies

  2020cites this paper
• An Evidence-Based Review of Galcanezumab for the Treatment of Migraine

  2020cites this paper
• Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide

  2020cites this paper
• Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache

  2020cites this paper
• Galcanezumab for the prevention of cluster headache

  2020cites this paper
• Thymoquinone exhibits anti-inflammatory, antioxidant, and immunomodulatory effects on allergic airway inflammation

  2019cites this paper
• Gender and Migraine

  2019cites this paper
• Sex Hormones and CGRP

  2019cites this paper
• Dural Calcitonin Gene-Related Peptide Produces Female-Specific Responses in Rodent Migraine Models

  2019cites this paper
• Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class

  2019cites this paper
• Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy

  2019cites this paper
• Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review

  2019cites this paper
• A Popperian View on Anti‐CGRP Biologics in Migraine

  2019cites this paper
• Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies : Adverse Effects . What Do We Really Know ? A Literature

  2019cites this paper
• CGRP, Amylin, Immunology, and Headache Medicine

  2018cites this paper
• A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

  2018cites this paper
• Galcanezumab in chronic migraine

  2018cites this paper
• Galcanezumab: First Global Approval

  2018cites this paper
• Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies

  2018cites this paper
• History and Review of anti‐Calcitonin Gene‐Related Peptide (CGRP) Therapies: From Translational Research to Treatment

  2018cites this paper
• Phase I, Randomized, Double‐blind, Placebo‐controlled, Single‐dose, and Multiple‐dose Studies of Erenumab in Healthy Subjects and Patients With Migraine

  2018cites this paper
• CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial.

  2018cites this paper
• Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects

  2017cites this paper
• Calcitonin gene-related peptide and pain: a systematic review

  2017cites this paper
• Gender aspects of CGRP in migraine

  2017cites this paper
• The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine

  2017cites this paper
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

  2017cites this paper
• Capsaicin in attenuating metabolic syndrome

  2017cites this paper
• CGRP als therapeutisches Ziel in der Therapie von primären Kopfschmerzen

  2017cites this paper
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Galcanezumab, a Monoclonal Antibody to Calcitonin Gene-Related Peptide, in Healthy Japanese and Caucasian Subjects

  2017cites this paper
• Phase 1 , Randomized , Double-blind , Placebo-controlled , Single-dose and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine

  2017cites this paper
• The influence of migraine and female hormones on capsaicin-induced dermal blood flow

  2017cites this paper
• Neue Therapieoptionen bei Migräne

  2016cites this paper
• TIPS 1346 No . of Pages 10 Review Wiping Out CGRP : Potential Cardiovascular Risks

  2016cites this paper
• Anti-CGRP monoclonal antibodies in migraine: current perspectives

  2016cites this paper
• Heteroreceptors Modulating CGRP Release at Neurovascular Junction: Potential Therapeutic Implications on Some Vascular-Related Diseases

  2016cites this paper
• Wiping Out CGRP: Potential Cardiovascular Risks.

  2016cites this paper
• Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.

  2015cites this paper
• Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead

  2014cites this paper
• Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

  2014cites this paper